Chauny

WAYFIND-R is a global registry focused on collecting high-quality real-world data from cancer patients diagnosed with solid tumors who have undergone next-generation sequencing (NGS) testing. The registry aims to support clinical and epidemiological research, generate evidence to better understand health outcomes and cancer care, and describe treatments and clinical courses for these patients. Participants must be adults diagnosed with any type of solid tumor at any disease stage and have had NGS testing within three months before enrollment. The study collects data without assigning specific treatments or interventions, instead tracking clinical characteristics and outcomes over time. During the study, researchers will gather information linking NGS results to treatments and patient outcomes, including overall survival for up to five years from enrollment. Participants provide informed consent, and data collected will help improve understanding of solid tumor cancers and their management in real-world settings.

Researchers are investigating a new approach to immunotherapy duration for patients with metastatic non-small cell lung cancer (NSCLC). This phase II-III randomized trial focuses on patients with stage IV NSCLC who have not received prior treatment for advanced disease. The study aims to compare the standard two-year immunotherapy maintenance with a shorter six-month (27-week) treatment period in patients who achieve disease control after initial chemo-immunotherapy induction, addressing the need to optimize treatment duration while maintaining disease control. Participants will first receive a combination of chemotherapy and pembrolizumab as initial treatment: either paclitaxel-carboplatin for squamous cell carcinoma (SCC) patients or pemetrexed-platinum for non-SCC patients, along with pembrolizumab every three weeks. After six months, patients who show disease control without severe toxicity will be randomly assigned to either continue pembrolizumab (with or without pemetrexed for non-SCC) until disease progression or unacceptable toxicity or complete two years of treatment, or to observation (with or without pemetrexed for non-SCC). Throughout the study, participants will undergo regular assessments including imaging to measure tumor response according to RECIST 1.1 criteria. Researchers will monitor overall survival at 18 months in phase II and about 24 months after randomization in phase III. Additional evaluations include performance status, PD-L1 expression, and safety monitoring. The total participation duration includes the initial six-month induction followed by the randomized maintenance or observation phase, allowing comprehensive evaluation of long-term outcomes and treatment impact.

Cancer patients often experience anxiety, nausea, and vomiting during chemotherapy, which can affect their quality of life. This research investigates the use of immersive virtual reality (VR) to help manage these symptoms in patients receiving their first line of chemotherapy. The study also measures the overall quality of life and satisfaction levels of both patients and nursing staff during treatment. The study is a controlled, randomized clinical trial with two groups: one group receives standard care with VR immersion using the Healthy Mind VR program during their first three chemotherapy sessions, while the other group receives standard care without VR. The trial includes a pre-inclusion visit 7 days before starting chemotherapy, treatment visits during three chemotherapy cycles, and follow-up visits at 3, 6, and 9 months after chemotherapy completion. Participants will complete quality of life questionnaires and satisfaction surveys, and anxiety, pain, depression, fatigue, nausea, and vomiting will be measured using various tools such as the QLQ-C30 questionnaire, Visual Analogue Scale, HAD score, and MASCC Antiemesis Tool. Patient and nurse satisfaction with chemotherapy procedures will also be assessed. Monitoring occurs at multiple points including before and after chemotherapy cycles and during follow-up visits up to 9 months post-treatment.